Gail Schwartz, MD
Ophthalmology · Baltimore, MDNPI 1184619819
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,314 of the $84,984 with a category attached, or 71.0%. Aerie Pharmaceuticals, Inc. accounts for 64.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $29,207 and has fallen 97.1% since, to $860 in 2025. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $381.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$54K
- AbbVie$24K
- Alcon$5K
- NEW World Medical,inc.$405
- Bausch & Lomb, A Division Of Bausch Health US, LLC$223
- Bausch & Lomb Americas Inc.$223
- plus $543 from 10 others
Across 4 payments — averaging $10,742 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aerie Pharmaceuticals, Inc.$43K
What the payments were for
- Consulting fees$15,94219%
- Speaking & faculty fees$60,31471%
- Travel & lodging$3,0234%
- Food & beverage$5,5847%
- Education$400%
- Gifts$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 42 | $54,366 |
| AbbVie(2 entities) | 118 | $23,832 |
| Alcon | 16 | $5,393 |
| NEW World Medical,inc. | 3 | $405 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $223 |
| Bausch & Lomb Americas Inc. | 11 | $223 |
| Harrow Eye, LLC | 2 | $123 |
| Glaukos Corporation | 3 | $109 |
| Sight Sciences, Inc. | 4 | $83 |
| Sun Pharmaceutical Industries Inc. | 3 | $61 |
| Integra Lifesciences Corporation | 1 | $50 |
| Thea Pharma Inc. | 2 | $40 |
| Iridex Corporation | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$58,746
- Rhopressa$51,302
- LUMIGAN$11,508
- DURYSTA$6,748
- COMBIGAN$4,662
- Ahmed Glaucoma Valve$364
- Kahook Dual Blade$364
- XEN GLAUCOMA TREATMENT SYSTEM$123
- XEN$109
- VEVYE$101
How this compares
$84,984 in reported general payments places this provider in the 95th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 570 | $345,825 |
| CombiganBrimonidine Tartrate/Timolol | 79 | $37,926 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 114 | $34,693 |
| RocklatanNetarsudil Mesylat/Latanoprost | 42 | $30,399 |
| Travoprost | 123 | $27,728 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 109 | $26,552 |
| Latanoprost | 1,387 | $25,059 |
| RhopressaNetarsudil Mesylate | 41 | $24,214 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 875 | $21,394 |
| VyzultaLatanoprostene Bunod | 37 | $18,769 |
| Alphagan PBrimonidine Tartrate | 33 | $15,305 |
| Brinzolamide | 61 | $14,639 |
| RestasisCyclosporine | 14 | $12,710 |
| Prednisolone Acetate | 216 | $10,648 |
| AzoptBrinzolamide | 15 | $10,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $23,832 | $411,766696 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $54,366 | $54,61383 claims |
| AlconSimbrinza, Azopt | $5,393 | $45,202129 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $223 | $18,76937 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa | $223 | $13,83664 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Baltimore
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Neil BresslerBaltimore$265K
- Adrienne ScottBaltimore$170K
- Jennifer ThorneBaltimore$128K
- Earl CravenBaltimore$120K
- Peter CampochiaroBaltimore$103K
- John GottschBaltimore$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.